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Orthotopic liver transplantation is frequently associ-
ated with hyperfibrinolysis. the origin and clinical rel-
evance of which is largely unknown. In 20 orthotopic 
liver transplantations, we studied the occurrence and 
systemic effects of hyperfibrinolysis. Severe fibrinolysis 
was defined to be present when the euglobulin-clot lysis 
time and the whole-blood-clot lysis time, as measured 
by thrombelastography, were shorter than 60 and 90 
min, respectively, at some time during the operation. 
Based on these criteria, 7 patients had minimal fibri-
nolysis (group I), and 13 patients had severe fibrinolysis 
(group IT). In group II a gradual increase of tissue-type 
plasminogen activator (t-PA) activity was seen during 
the an hepatic stage, followed by an "explosive" increase 
immediately after graft reperfusion (P=0.0004, com-
pared with group I), and a reduction of plasminogen 
activator inhibitor (PAl) activity. Plasma degradation 
products of fibrinogen and fibrin increased parallel to 
toP A activity, and levels were significantly higher at 45 
min after graft reperfusion in group II compared with 
group I (P<0.04). Thrombin-antithrombin III com-
plexes showed an identical steady increase in both 
groups, indicating that increased t-PA activity was not 
related to thrombin formation. A combination of in-
creased endothelial release and reduced hepatic clear-
ance may have caused the increased t-PA activity. The 
top A-associated destruction of fibrinogen and fibrin 
after graft reperfusion is consistent with the clinical 
signs of severe oozing often seen in this period. These 
observations may have important clinical implications 
for the treatment of bleeding in patients undergoing 
orthotopic liver transplantation. 
Orthotopic liver transplantation has become an accepted and 
clinically useful treatment for patients with a variety of irre· 
versible liver disease (1). The gradual improvements of the 
surgical technique, anesthesiologic management, and immu· 
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nosuppressive therapy have contributed to an increase in the 
success rate and long-term survival (1,2). The surgical opera-
tion however is an extensive procedure, which may be fre-
quently associated with serious bleeding, requiring massive 
blood transfusions (3). Maintenance of surgical hemostasis may 
be seriously complicated by disturbances in the hemostatic 
system. Previous studies have suggested an important role of 
hyperfibrinolysis in the origin of bleeding complications during 
orthotopic liver transplantation (4, 5). 
Recently, studies involving only a few subjects have shown 
that the hyperfibrinolysis during orthotopic liver transplanta· 
tion may be related to increased plasma levels of tissue-type 
plasminogen activator (t·PAl* (6, 7), a key enzyme of the 
fibrinolytic system (8). Under normal physiologic conditions, 
t·PA activity in the circulation is low, due to its rapid inacti· 
vation by formation of complexes with PA-inhibitors (PAl), 
but t·PA activity may increase several fold after specific stimuli 
(8). Both t-PA and its major inhibitor (PAI·l) are produced 
and secreted by endothelial cells, whereas hepatocytes and 
blood platelets are additional sources of PAl·! (8, 9). Elimi-
nation of t·PA from the blood is mainly regulated by the liver 
with a tl/2 of 3-5 minutes (10). Increased levels of t·PA during 
orthotopic liver transplantation probably result from a combi· 
nation of increased endothelial release and decreased hepatic 
clearance during the anhepatic stage (6). The mechanisms 
underlying the increased release of t-PA and the role of PAl in 
the regulation of t·PA activity during liver transplantation 
however are still unknown. 
Some investigators have suggested that hyperfibrinolysis in 
orthotopic liver transplantation may be secondary to dissemi· 
nated intravascular coagulation (DIe) (7, 11, 12), Differentia-
tion between secondary and primary fibrinolytic activity how· 
ever has been difficult, mainly due to lack of appropriate 
laboratory tests. Lack of specific parameters has also hampered 
the assessment of the role of increased fibrinolytic activity in 
the actual breakdown of coagulation factors and the develop· 
ment of a bleeding diathesis. Especially under strongly hyper· 
fibrinolytic conditions, fibrinogenolysis may also occur (13). 
Although increased serum levels of fibrin(ogen) degradation 
• Abbreviations: AU, arbitrary units: DIe, disseminated intravascu· 
lar coagulation: EL T, euglobin clot lysis time: FbDP, fibrin degradation 
products; FgDP, fibrinogen degradation products; PAl, plasminogen 
activator inhibitor; TAT, thrombin· antithrombin 11\; TEG. thrombe-
lastography; t·PA. tissue·type plasminogen activator; WBLT, whole 
blood cIot lysis time. 
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products have been found during liver transplantation (4, 11), 
whether these were the result of fibrin breakdown or plasmin 
destruction of fibrinogen could not be determined. 
In the present study, we examined the origin and clinical 
relevance of hyperfibrinolysis in orthotopic liver transplanta· 
tion. Measurement of t-PA and PAl activity in combination 
with the separate quantitation of plasma degradation products 
of fibrinogen and fibrin enabled us to study the origin of 
hyperfibrinolysis and its role in the development of a systemic 
lytic state. Thrombin-antithrombin III (TAT) complexes were 
measured to study the role of clotting activation and thrombin 
formation in the origin of hyperfibrinolysis. 
MATERIALS AND METHODS 
patil!nts. Twenty·three adult patients who underwent their first liver 
transplantation at Presbyterian University Hospital between June 1 
and 2;,1988 were observed prospectively. In an otherwise consecutive 
series, 3 patients, of whom more than 2 blood samples were missing 
due to technical errors, were omitted. The remaining 20 patients were 
categorized by pathological diagnosis as described previously (14). Five 
different diagnostic groups could be distinguished, as shown in Table 
1. Orthotopic liver transplantation was performed by a standard tech· 
nique, using a venovenous bypass in all patients (I5). The surgical 
procedure can be divided into 3 stages. During the preanhepatic stage 
(stage I), the host Liver is isolated. The anhepatic stage (stage II) begins 
with the clamping of the vessels of the native liver and ends with the 
completion of the vascular anastomosis of the graft Liver. The postan-
hepatic stage (stage III) lasts from graft reperfusion to the end of 
surgery. Intraoperative blood loss was compensated by the transfusion 
of modified whole blood (from which platelets have been removed) or 
packed RBC and fresh frozen plasma in an approximate ratio of 1:1. 
In case of massive blood loss, a rapid infusion system was used, by 
which a mixture of packed RBC, fresh-frozen plasma, and Plasmalyte 
A was infused in a ratio of 1 U:l U:250 mL Platelets and cryoprecipitate 
were usually not given before stage Ill. All patients gave their informed 
consent for blood sampling during the operation, as part of the intra-
operative patient care. 
Intraoperative blood samples for hemostasis monitoring were col-
lected from an arterial line. Blood (9 mil was coJIected in 1 ml 0.13 
moUL trisodium citrate and immediately centrifuged at 2800xg for 10 
min. Plasrna was either directly used for testing or frozen at -70°('. 
Whole blood (0.36 rnl) was used for thrornbelastographic rnonitoring 
within 2 rnin after sampling. Blood samples were taken according to 
the following schedule: immediately after inductIOn of anesthesia 
(BASEl; 30 min before removing the liver (11-301: 5 min in the anhe-
patic stage (11+5'; 5 min before graft reperfusion (III-5,; 5 min after 
graft r£'perfusion 011+5); 45 min after reperfusion !II1+45,; 150 min 
after reperfusion (1I1+150), and at the end of the operation (E]'I;DI. 
Assays Standard hemostasis tests were performed using previously 
described methods (16, 17). Thrombelastographic monitoring of whole 
blood coagulation and fibrinolysis was performed using a Thromb 
Elastograph-D (Haemoscope Corporation, Morton Grove, IL). The 
whole blood clot lysis time (WBL T) was defined as the time between 
TABLE 1. Diagnosis and characteristics in 20 patients undergoing 
orthothopic liver transplantation 
Diagnosis No. F M Age range 
Post necrotic cirrhosis 9 3 6 27-54 
Primary biliary cirrhosis 5 5 27-60 
Sclerosing cholangitis 3 2 29-41 
Carcinoma 1 1 63 
Miscellaneous· 2 1 1 22,37 
Total 20 10 10 22-63 
• Two patients with Wilson's disease. 
the maximum amplitude and the registration of complete lysis on the 
thrombelastographic recording (normal >150 min) (18). 
Levels of t-PA activity (normal range, 0-1 IU/ml) and PAl activity 
were measured using chromogenic substrate methods (Coasets t-PA 
and PAl, Kabi Vitrum Hematology, Stockholm, Sweden). For the 
measurement of t-PA activity, 100 III of plasma was acidified (pH 4.0-
4_1) with 100 III of acetate buffer and 20 III of 20% acetic acid, both 
supplied in the assay kit. T-PA activity was determined by measuring 
the amidolytic activity of plasmin onto the chromogenic substrate S-
2251, after incubation in the presence of plasminogen and human 
fibrin(ogen) fragments (19,20). The fibrinolytic activity of t-PA was 
expressed in International Units assessed by calibration against the 
international standard of t-PA from human melanoma cells (\ot 83/ 
517, National Institute for Biological Standards and Control, London, 
UK). PAl activity was measured by adding 40 IU/ml t-PA to an equal 
volume of plasma. After incubation for 10 min at room temperature, 
samples were diluted with sterile water (1:80), and residual t-PA activity 
was determined as described above. PAl activity was expressed in 
arbitrary units (AU), defined as the amount tbat inhibits 1 IV of t-PA 
in 10 min (21) (normal, 0-40 AU/mI). 
Two different sandwich-type enzyme-linked immunosorbent assays 
(Fibrinoatika, Organon Teknika, Tumhout, Belgium) were used for the 
quantitation of plasma levels of fibrinogen degradation products 
(FgDP; normal <0.5 Ilg/ml) and fibrin degradation products (FbDP; 
normal <0.5 Ilg/ml). In both ELISAs, a monoclonal antibody, which 
reacts exclusively with FgDP and FbDP and not with intact fihrinogen 
or fibrin, is used 88 catching antibody. The FgDP ELISA contains a 
monoclonal tagging antibody that is specific for covalently bound 
fibrinopeptide A_ Since fibrinopeptide A is split off during the activa-
tion of fibrinogen by thrombin, this ELISA tags only FgDPs tbat result 
from the plasmin-mediated destruction of fibrinogen (22). The FbDP 
ELISA gets its specificity for FbDP by using a monoclonal antibody 
that is elicited with D-dimer as immunogen (23). 
TAT complexes (normal range, 1.0-4.1 Ilg/L) were measured by an 
ELISA (Behringwerke. ~larburgK FRG), based on rabbit antibodies to 
human thrombin and antithrombin III, respectively (24). Samples with 
TAT levels exceeding the highest standard contained in the assay kit 
(60 Ilg/L), were diluted (1:2 or 1:4) in normal pooled plasma, which had 
been shown to have a TAT concentration of 1.2 .. g/ml. 
Statistical analysis Statistical analysis was performed using the 
NPARl WA Y computer program of the Statistical Analysis System 
(SAS Institute Inc .. Cary. :"IiC). The significance of differences within 
and between groups were tested using the Wilcoxon rank-sum test and 
two-sample test. respectively. Values for P<0.05 were considered to be 
significant. 
In all but 1 patient, slightly to severely increased fibrinoh1ic 
activity, as measured by shonening of the euglobulin clot l~Dsis 
time (ELT; normal >120 min) or WBLT (normal >150 ~inFI 
was found in at least 1 blood sample during the operation. 
Signs of hyperfibrinolysis were most frequent at the end of the 
anhepatic stage and early after graft reperfusion of the donor 
liver. Fibrinolysis was defined as minimal if the EL T was longer 
than 60 min or when the WBL T was longer than 90 min in all 
blood samples_ Severe fibrinolysis was defined as being present 
when the EL T and WBL T were shorter than 60 and 90 min, 
respectively, in at least one ofthe intraoperative blood samples. 
According to these criteria, the patients were divided into 2 
groups. Group I was formed by 7 patients with minimal fibri-
nplysis. Group II consisted of 13 patients with severe fibrinoly-
sis. Comparison of the preoperative hemostasis parameters 
showed no significant differences between the 2 groups (Table 
2). Both groups included patients with different diagnoses, 
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TABLE 2. Comparison of preoperative hemostasis profile in patients with minimal (group J) and severe (group II) intraoperative fibrinolysis 
Variables Reference values 
Coagulation: 
PT (sec) 10.S-13.0 
amqqE~F 26-34 
qhqE~F 13-18 
Fibrinogen (mg/dl) 150-450 
Factor II (%)" 50-150 
Factor VIII (%)" 50-150 
TAT complex (I'g/ml) 1.0-4.1 
Platelets (1 OS IL) 150-450 
Fibrinolysis: 
ELT (min) >120 
WBLT (min) >150 
t-PA act. (IU/ml) 0-1.0 
PAl act. (IU/mI) 0-40.0 
FgDP (llI/mI) <0.5 
FbDP (I'g/ml) <0.5 
• Percentage of pooled normal pluma. 
• For ail patients. 
without an accumulation of any diagnostic group in either of 
the 2 groups. 
Mean intraoperative levels oft-PA activity and PAl activity 
of group I and II are depicted in Figure 1. There were no 
significant changes in t-PA and PAl activity during the prean-
hepatic stage in both groups. In group I t-P A levels remained 
below 12 IV /ml during the rest of the operation in all patients. 
In group II t-P A activity increased after clamping of the vessels 
of the native liver. and levels were significantly higher at the 
end of the anhepatic stage (II1-5), compared with group I 
(P=O.OO2). During reperfusion of the graft. t-PA levels in-
creased sharply. resulting in a more than doubling at 5 min 
after reperfusion. compared with the values at 5 min before 
reperfusion (P<O.OO7). At this time t-PA activity in group II 
(65.1±8.5 IV/mi. mean ±SEM) was about 30 times higher than 
the preoperative value and more than 10 times higher than t-
PA activity in group I (P=0.OOO4). Later in the postanhepatic 
stage, a rapid disappearance of t-PA activity was seen. and 
levels fell into the normal range (0-1 IU/m!) at the end of the 
operation in all but 2 patients. In these 2 patients t-PA levels 
were still moderately increased (3.4 and 10 IU/mi). In group II 
free PAl activity showed a pattern inverse that of t- PA activity. 
and only minimal PAl activity (1.l±0.7 AU/ml, was left at the 
peak of fibrinolytic activity. but levels increased during the 
later postanhepatic period in both groups. 
Mean plasma levels of FbDP and FgDP in groups I and II 
are shown in Figure 2. Although an increase of FbDP and FgDP 
was seen in both groups. levels in group II were significantly 
higher in the postanhepatic period at 45 min after graft reper-
fusion when compared with group I (P<O.04l. In group II the 
highest FgDP level (lS.4±7.9 I'g/ml) coincided with the peak 
in t-PA activity (11+5), whereas the maximum in FbDP (32.5± 
11.2 ~g/mlF occurred somewhat later in the postanhepatic stage 
(III+45). 
Mean levels of TAT complexes in group I and II are shown 
in Figure 3. An identical increasing pattern was seen in both 
groups. and at none of the time points were TAT levels signif-
icantly cliffe rent between the 2 groups. Highest TAT levels 
were found during the postanhepatic stage. and levels were still 
Median (range) 
-
Group I Group II 
---
11.3 (10.4-21.2) 12.2 (9.7-21.2) 
36.0 (28.9-51.6) 42.9 (29.1-127) 
17.1 (15.3-32.9) 22.0 (14.3-47.7) 
285 (159-460) 140 (85-350) 
66 (32-130) 38 (15-135) 
185 (130-300) 120 (82-280) 
8.0 (2.0-16.0) 4.3 (1.6-60.0) 
81 (56-510) 118 (39-336) 
>120 (105->120) 60 (15->120) 
>150· >150· 
2.4 (0-6.0) 1.4 (0-8.0) 
18.5 (14.0-36.0) 18.8 (3.0-37.5) 
0.28 (0.20-3.0) 0.50 (0.20-2.6) 
0.30 (0.26-4.5) 0.84 (0.22-6.0) 
above the normal upper limit (>4.1 "gIL) at the end of the 
operation in ail patients. 
Comparison of changes in arterial pH, p02, and blood pres-
sure in group I and II are shown in Table 3. There was no 
evidence for a relationship between intraoperative changes in 
hemodynamics and the increase in t-PA activity. Periods of 
shock, as determined by a drop in blood pressure and pH. were 
found among both patients with high and low t-PA activities. 
The intraoperative use of blood products is shown in Table 
4. There were no differences in the use of cryoprecipitate and 
platelets between the 2 groups. However. intraoperative blood 
loss, as reflected by the total use of modified whole blood or 
packed RBC and fresh-frozen plasma. was significantly higher 
in group II than in group I (P<0.02). 
DISCL'SSIO:\ 
In earlier studies we have found that increased fibrinolytic 
activity, as measured by the EL T or thrombelastography 
lTEG), occurs in about UM~ of the patients undergoing ortho-
topic liver transplantation (18, 25). Fibrinolytic activity may 
mcrease during the anhepatic stage and is most often severe 
early after graft recirculation. A simultaneous decrease of plas-
minogen and a"-antiplasmin, the main inhibitor of plasmin, 
has been found during this period, which supports the view of 
an active fibrinolytic process (5). However, the use of EL T and 
TEG in these studies did not allow an exact characterization 
of the fibrinolytic defect. and the origin and clinical relevance 
of the increased fibrinolytic activity have remained largely 
unclear. 
In this study we found an extreme increase of t-PA activity, 
and concomitant decrease of PAl activity during the anhepatic 
and early postanhepatic period in patients with severe fibri-
nolysis, as measured by the ELT and TEG. Reduction in PAl 
activity can be explained by the formation of complexes with 
t-PA. After saturation of free PAl, a further increase of t-PA 
will result in the increase of free t-PA activity in the circulation 
(9, 21). Recently. Dzik et al. (6) and Palareti et al. (7) have 
reported a similar increase of t-PA during the anhepatic stage 
in a limited number of patients undergoing OL T. However. 
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FiGURE 1. Intraoperative levels of t-PA activity and PAL activity 
(mean ±SEM) in patients with minimal (0-0, group I, n=7) and 
severe fibrinolysis E~I group II, n=13). Each tic on the abscissa 
indicates 1 hr_ The area between the dotted lines represents the 
anhepatic stage (stage 11). 
these studies did not show the explosive t-PA increase. occur-
ring directly after graft reperfusion, as seen in our patients. 
Since we observed a rapid normalization of t-PA activity after 
its maximum, this peak could have been easily missed in the 
other studies if no blood samples were taken within 10 min 
after reperfusion, 
The intraoperative course of t- PA activity suggests that there 
are 2 different mechanisms responsible for the increase of t-
PA during orthotopic liver transplantation. The initial rise of 
t-PA during the anhepatic stage has been explained by a 
combination of increased release of t-PA and reduced hepatic 
clearance (6). This view is supported by the lack of fibrinolytic 
activation during auxiliary, heterotopic liver transplantation in 
which the native liver is not removed (26, 27). Dzik et aL (6) 
found that increase of t-PA during orthotopic liver transplan-
tation may be associated with signs of shock, They suggested a 
mechanism of increased t-PA release due to hypotension and 
acidosis. We could not find any differences in blood pressure, 
arterial pH, or p02 in patients with high or low t-PA levels. 
Probably mechanisms other than changes in the arterial cir-
culation may also attribute to an increased release of t-PA_ 
Patients with liver disease are known to be prone to activation 
of their fibrinolytic system upon specific stimuli such as phys-
ical stress and exercise (28, 29). The surgical stress, with the 
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FIGURE 2. Intraoperative levels (mean ±SEM) of fibrinogen deg-
radation products (FgDP) and fibrin degradation products (FbDP) in 
orthotopic liver transplantation .. J....---O, group I: patients with mini-
mal fibrinolysis En=T1;~: Group II: patients with severe fibri-
nolysis (n=13). Each tic on the abscissa indicates 1 hr. The area 
between the dotted lines represents the anhepatic stage (stage II), 
manipulations and extensive trauma to the vascular bed and 
abdominal circulation therefore might have contributed to an 
increased release oft-PA, 
The rapid increase during graft reperfusion suggests a second 
mechanism that is associated with the restoration of blood flow 
through the donor liver. In studies with pigs, we recently 
demonstrated that fibrinolytic activity in the hepatic venous 
outflow immediately after graft reperfusion is significantly 
higher than the fibrinolytic activity in the systemic circulation 
(Porte RY, Blauw E, Knot EAR, 1988, unpublished data). 
These data, in combination with the "explosive" t-PA increase 
after reperfusion in this study, strongly suggest an increased 
release of t-PA from the reperfused donor liver. Several factors, 
including vasoreactive agents, venous occlusion, anoxia, and 
thrombin, have been found to stimulate t-PA release from 
endothelial cells in in vitro and in vivo studies (8, 30, 31). It 
can be theorized that, during graft reperfusion and the subse-
quent restoration of normal portal blood flow, one or more of 
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FIGURE 3. Intraoperative levels (mean ±SEM) of thrombin-anti-
thrombin III (TAT) complexes in orthotopic liver transplantation. 
0--0, group I: patients with minimal fibrinolysis (n=7); _____ , 
group II: patients with severe fibrinolysis (n=13). Each tic on the 
abscissa indicates 1 hr. The area between the dotted lines represents 
the anhepatic stage (stage II). 
TABLE 3. Comparison of intraoperative hemodynamic changes in 
patients with low (group I) and high (group II) t-PA activity 
Hemodynamics 
At the end of stage ,,: 
Arterial pH" 
Arterial pO, (mm Hg) 
No. patients with a hy-
potensive period 
Early in stage III: 
Arterial pH 
Arterial pO, (mm Hg) 
No. patients with a hy-
potensive period 
Group 1 In=i) 
7.37 (7.33-7.45) 
218 (113-311) 
1/TE14~1 
7.31 (7.22-7.42) 
272 (150-486) 
Group II (n=13) 
7.40 (7.34-7.46) 
279 (122-397) 
3/13 EOP~F 
7.32 (7.15-7.42) 
275 (114-531) 
5/13 (38se) 
" The pH and pO 2 are expressed in median' range). 
TABLE 4. Intraoperative blood use in patients with low (group Il and 
high (group II) t-PA activity 
RBC" (n Mean 5 19 
Median (rangel 4 (1-8) 10 (3-1011 
FFP (V) Mean 1 11 
Median (range) 0(0-8) 4 (0-68) 
RBC + FFP (0) Mean 6 30 
Median (range) 4 (2-16) 10 (3-169) 
Cryoprecipitate (U) Mean 0 3 
Median (range) O· 0(0-12) 
Platelets (U) Mean 3 5 
Median (range) 0(0-10) 8 <0-28) 
" RBC includes packed red blood cells and modified whole blood. 
b For all patients. 
these factors, or leakage from ischemic damaged endothelial 
cells, contribute to an increase of t-PA. The normalization of 
t-PA activity during the late postanhepatic stage can be ex-
plained by the restoration of the normal hepatic clearance of t-
PA after the implantation of a viable donor liver. Reduction of 
t-PA activity might have been enhanced by an increase of PAl 
toward the end of the operation, which is generally seen after 
major surgery and which is consistent with the behavior of PAl 
as an acute phase reactant (32). 
Some investigators have suggested that hyperfibrinolysis in 
orthotopic liver transplantation may be secondary to thrombin 
formation during DIe (7, 11). For several reasons we do not 
believe that DIe is the main cause of t-PA increase during 
orthotopic liver transplantation. 
First of all, in large series of patients, we previously found 
no evidence for a combined decrease of coagulation factors and 
inhibitors, as occurs during DIe (24,33). Repeatedly negative 
findings regarding thromboembolic processes in histopatho-
logic and clinical examination support the view that DIC does 
not playa clinically important role in OLT (34,35). 
Second, this study provided evidence for a thrombin-inde-
pendent increase in t-PA during liver transplantation. Al-
though TAT complexes, which are formed early during clotting 
activation by complex formation between thrombin and anti-
thrombin III (24), increased steadily from the beginning of the 
operation and were still elevated at the end of the operation, t-
PA increase was clearly limited to the an hepatic and early 
postanhepatic stage. Additionally, there was no difference in 
TAT increase in patients with high or low t-PA levels, indicat-
ing that the t-PA increase was independent of thrombin for-
mation. The rise in TAT levels in our patients was most 
probably a sign of local clotting activation at the wound surface. 
Further studies, preferably with patients undergoing other ma-
jor abdominal surgical procedures as control group, however, 
are necessary to establish the role of increased TAT levels in 
orthotopic liver transplantation. 
Third, secondary fibrinolysis during DIe is probably a more 
local process that does not result in detectable increased fibrin-
olytic activity in the systemic circulation. In an analysis of 346 
patients with DIe, Spero et al. (36) found evidence of systemic 
fibrinolytic activation. as demonstrated by shortened EL T or 
recalcified clot lysis time, in only lOe; of the patients. Francis 
and Seyfert (37) recently demonstrated that although t-PA 
antigen is elevated in patients with DIe, detectable free t-PA 
activity is less frequently present than in hospitalized controls. 
These investigators concluded that PAl levels are also increased 
in Die, leading to masking of the increased endothelial secre-
tion of t-PA. This \'iew is supported by experiments with 
cultured endothelial cells in which thrombin was shown to 
stimulate the release of both t-PA and PAl (30), resulting in 
no detectable net free t-PA activity despite increased levels of 
t-PA antigen. We observed a 40-50-fold systemic increase of t-
P A activity and a concomitant saturation of PAl, resulting in 
a decrease of free PAl activity during the period of hyperfibri-
nolysis. Another process than DIC therefore seems responsible 
for the increased t-PA activity in orthotopic liver transplanta-
tion. Why some patients develop a high increase of t-PA 
activity, whereas others do not. remains unclear. We could not 
find any difference in diagnosis, preoperative hemostasis pro-
file, or intraoperative hemodynamics in patients with high or 
low intraoperative t-PA activity levels. 
Irrespective of its origin, the extremely high t-PA levels 
during the early postanhepatic stage may be clinically impor-
tant. Especially in this period, formation of fibrin and stable 
hemostatic clots is necessary to prevent or stop bleeding from 
the vascular anastomosis and the extensive wound surface. 
Although the systemic increase of t-PA activity had a transient 
character, the clinical effect may extend over a considerably 
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longer period, as t-PA may bind.to fibrin and ?ec~me incorp~­
rated in newly formed hemostatiC clots, resultmg m early lYSIS 
and delayed bleeding from fresh wounds (38). The role of t-PA 
in the development of a systemic lytic state was demonstrated 
in this study by the increase of plasma levels of both FbDP and 
f'gDP in patients with high t-PA levels. This confirms earlier 
studies, which suggested a plasmin-mediated destruction of 
coagulation factors during orthotopic liver transplantation (5, 
33). FgDPs are known to have an anticoagulant effect by 
inhibiting the polymerization of fibrin monomers into cross-
linked fibrin (39). The occurrence of FgDPs in the circulation 
therefore may well be attributed to a further deterioration of 
the hemostatic function in patients undergoing orthotopic liver 
transplantation, as has been suggested before by Blecher et a1. 
(40). The peak of FbDPs in the early postanhepatic stage is 
consistent with the clinical picture of delayed oozing and in-
creased blood loss in this period (I8, 25). We indeed found an 
significantly higher blood loss in patients with severe fibrinoly-
sis (group II). However, these data should be interpreted with 
some reserve, as blood loss is influenced by multiple factors 
and larger series of patients are necessary to confirm this 
observation. 
Since the primary increase in t-PA activity was associated 
with an active proteolytic destruction of fibrinogen, and fibrin 
and a high blood loss, the use of antifibrinolytic drugs seems 
justified in patients with life-threatening hemorrhages where 
active fibrinolysis is likely. To identify these patients, it is 
advisable to include at least 1 test method for the assessment 
of fibrinolytic activity in the intraoperative hemostasis moni-
toring in orthotopic liver transplantation. 
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T CELL DEPLETION OF HUMAN BONE MARROW 
COMPARISON OF CAMPATH-l PLUS COMPLEMENT, ANTI-T CELL RICIN A CHAIN IMMUNOTOXIN, AND 
SOYBEAN AGGLUTININ ALONE OR IN COMBINATION WITH SHEEP ERYTHROCYTES OR IMMUNOMAGNETIC 
BEADS! 
JAMES N. FRAME,2 NANCY H. COLLINS, TERESA CARTAGENA, HERMAN WALDMANN,3 
RICHARD J. O'REILLY, Bo DUPONT, AND NANCY A. KERNAN4 
Human Immunogenetics Laboratory and Bone Marrow Transplantation Service, Memorial Sloan-Kettering Cancer Center, 
New York, New York. and Department of PatMlogy, University of Cambridge. Cambridge. United Kingdom 
The aim of this study was to compare the extent of in 
vitro T cell depletion and recovery of hematopoietic 
progenitor cells achieved with five methods of T cell 
depletion. Bone marrow samples from the same source 
were treated with monoclonal antibody Campath-l 
(CPl) and human complement, XomaZyme-H65 (anti-
T cell ricin A chain immunotoxin), or soybean agglutinin 
(SBA) alone or in combination with sheep erythrocytes 
(EUT) or a cocktail of immunomagnetic beads (B) di-
rectly coated with anti-CD2. anti-CD3, or anti-CDS 
monoclonal antibodies. Residual T cells were enumer-
ated by limiting dilution analysis, EAET rosetting. and 
proliferative responses to phytohemagglutinin. The re-
sults of this study demonstrated the following reductions 
in BM T cells as detected by limiting dilution analysis 
(mean o/c contro\): SBA+B (99.9%), SBA+EM:T (99.S'7c), 
CPt +C' (99.4 '7d , anti-T cell ricin A chain immunotoxin 
(99.00/c), and SBA alone (94.2%). Neither PHA response 
nor enumeration of residual EAET rosettes provided dis-
criminating differences in the degree of T cell depletion 
I This work was supported by National Institutes of Health Grants 
CA 22507, CA 23766, CA 08748, as well as by the XOMA Corporation. 
Berkeley. CA. the Charles A. Dana Foundation. the Zelda Weintraub 
Cancer Foundation. the Robert J. Kleberg and Helen C. Kleberg 
Foundation. the Lila Acheson Wallace Foundation, the Andrew Gaff-
ney Foundation. and the Frito Lay IN ew York Yankees Challenge Fund. 
'J. F. is supported by postdoctoral National Institutes of Health 
Immunology Training Grant CA 09148-11. 
) University of Cambridge. 
• Address correspondence to: Nancy A. Kernan. M.D., Memorial 
Sloan-Kettering Cancer Center. 1275 York Avenue. New York, NY 
10021. 
2£ 
by treatment method when T cell reductions exceeded' 
99.0% by LDA. These results demonstrate the ability of 
CPl+C', XomaZyme-H65. and SBA plus sheep eryth-
rocyte or magnetic bead depletion to achieve a greater 
than 99% reduction of BM T cells and the importance of 
limiting dilution analysis in defining differences in T 
cell numbers when depletion exceeded 99%. 
Pretransplantation depletion of donor T cells from rodent 
( 1. 2) or human bone marrow grafts has produced significant 
reduction in the incidence and severity of acute graft -versus-
host disease (3-8). A number of methods for in vitro T cell 
depletion (TeD)" have been evaluated, including the use of 
monoclonal antibodyls) (MoAb) + complement (4-7). soybean 
agglutination (SBA) plus sheep erythrocJ1e deplet ion (.'i. 9), 
elutriation (10), anti-T cell ricin (]]) and ricin A chain im-
munotoxins (12 J, and immunomagnetic beads coated with 
anti-T cell MoAb (13). Methods for enumerating the extent of 
TCD have included E-rosette analysis, proliferative responses 
to phytohemagglutinin, and immunofluorescence analysis with 
anti-T cell MoAbs. However, quantitating residual BM T cells 
by E-rosette analysis, PHA response, and immunofluorescence 
with anti-T cell MoAb has not provided a consistent correlation 
between the number of residual T cells transplanted and the 
subsequent development or severity of GVHD (14-16). 
• Abbreviations: B, beads; BFU-E, burst-forming unit-erythroid; CD. 
cluster designation; CPl. Campath-1; EAI'T. 2-amino-ethyliosothiouron-
ium-treated erythrocytes; HSA, human serum albumin; SSA, soybean 
agglutinin; TCD, T cell depletion. 
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